Meeting
2019 ASCO Annual Meeting
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
Authors
Dejan Juric
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Dejan Juric , Sibylle Loibl , Fabrice Andre , J. Ignacio Delgado Mingorance , Frederic Forget , Christelle Levy , Norikazu Masuda , Mario Campone , Pier Franco Conte , Hiroji Iwata , Ingrid A. Mayer , Hope S. Rugo , Celine Wilke , Antonia Ridolfi , Agnes Lteif , Eva Ciruelos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02437318
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1038)
DOI
10.1200/JCO.2019.37.15_suppl.1038
Abstract #
1038
Poster Bd #
119
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
First Author: Hope S. Rugo
Poster
2021 ASCO Annual Meeting
Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).
First Author: Dejan Juric
First Author: Michelino De Laurentiis
Poster
2022 ASCO Annual Meeting
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.
First Author: Joyce O'Shaughnessy